

# There's a life behind every test

## Simplify Flu A+B testing

Streamline your point-of-care flu testing with the portable **BD Veritor™ Plus System**, which features intuitive operation and timely, reliable results.



\*EUA Authorized by FDA



# Overcome the challenges of flu season

FLU A+B

The **BD Veritor™ Plus System** offers simple operation, an efficient workflow, and fast, traceable results, which may help improve the patient experience.



## Simplifies the testing process

- Helps user operation with single-button functionality that can potentially reduce manual test processing errors
- Provides intuitive sample processing with prefilled, unitized tubes



## Delivers workflow efficiency

- Adapts easily to your workflow by offering 2 operational modes
  - » **Walk Away:** the test device is inserted into the Analyzer immediately after preparation, allowing staff to multitask while the sample incubates
  - » **Analyze Now:** the test device is inserted after the incubation time is complete, allowing batches of samples to be tested at once



## Achieves reliable, rapid results

- Displays easy-to-read digital results for flu in just 10 minutes<sup>1</sup>
- Provides clear, objective results by correcting for nonspecific binding and detecting positives not recognized by the unaided eye<sup>1</sup>



## Provides result traceability

- Stores or downloads the lot number, patient/specimen ID, operator ID and test records using the BD Veritor™ InfoWiFi module or via the companion ImageMover application
- Offers result printing capabilities via USB port


**Reference:** 1. BD Veritor™ Plus System for Rapid Detection of Flu A+B. Package insert. 8087667 Becton, Dickinson and Company.

BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA  
800-638-8663

**BDVeritor.com**

BD, the BD Logo and Veritor are trademarks of Becton, Dickinson and Company or its affiliates. © 2023 BD. All rights reserved. (BD-26925 2041-US-0323 March 2023)

## Proven performance vs PCR (CLIA-waived kit)<sup>1</sup>

	PPA <sup>†</sup>	NPA <sup>‡</sup>	Results in
<b>Influenza A CLIA-waived</b>	<b>83.6%</b> (76.1%, 89.1%)	<b>97.5%</b> (95.7%, 98.5%)	
<b>Influenza B CLIA-waived</b>	<b>81.3%</b> (71.1%, 88.5%)	<b>98.2%</b> (95.7%, 99.3%)	
<small>†positive percent agreement ‡negative percent agreement</small>			<b>Flu A+B results in 10 minutes</b>

## Empower your staff with the BD Veritor™ Plus eLearning online training platform

- Assigns customized training plans by role, product or learning type
- Simplifies learning through 5-minute modules
- Tracks training compliance and competency assessments

Ordering information	Cat no.	Qty
BD Veritor™ Plus System Flu A+B CLIA-waived kit	256045	30 tests
BD Veritor™ Plus System Flu A+B moderately complex kit	256041	30 tests
BD Veritor™ Plus Analyzer	256066	1 unit

\*EUA Information for the BD Veritor™ SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays: These products have not been FDA cleared or approved; but have been authorized by FDA under EUA for use by authorized laboratories. The BD Veritor™ System for Rapid Detection of SARS-CoV-2 has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, the emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

